DECC (dexamethasone, etoposide, chlorambucil, lomustine) as an oral chemotherapy regimen in relapsed and refractory diffuse large B-cell lymphoma

Br J Haematol. 2021 Feb;192(3):e92-e94. doi: 10.1111/bjh.17278. Epub 2020 Dec 18.

Authors

Jamie M Maddox¹, Matthew Horan², Laith Tafesh², Caroline Shrubsole², Wendy Osborne²

Affiliations

¹ Department of Haematology, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK.
² Department of Haematology, The Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK.

PMID: 33336792
DOI: 10.1111/bjh.17278

No abstract available

Keywords: Non-Hodgkin lymphoma; chemotherapy; clinical haematology.

Publication types

Letter

MeSH terms

Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Chlorambucil / administration & dosage
Chlorambucil / therapeutic use*
Dexamethasone / administration & dosage
Dexamethasone / therapeutic use*
Etoposide / administration & dosage
Etoposide / therapeutic use*
Female
Humans
Lomustine / administration & dosage
Lomustine / therapeutic use*
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy

Substances

Chlorambucil
Etoposide
Lomustine
Dexamethasone